Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, mpox, and their related conditions. During these 2-hour sessions, speakers present their research. The Oral Abstract Sessions are divided into two 1-hour segments, as described below. 2 combined question-and-answer sessions are held and moderated by experts in the field. Moderators introduce presenters and facilitate audience discussion during the live question-and-answer periods. 

See Also: Important Dates | Abstract Submission | Themed Discussion Guidelines | Poster Presentation Guidelines | Registration | Embargo Policy | FAQs

CROI Slide Template: Download the optional slide template here. 

Title Slide: A title slide prepopulated with your name, institution, and financial disclosures will be provided when you submit your final slides in the Speaker Ready Room at CROI.  

Note: The CROI presentation software can only accept PowerPoint slides (eg no Keynote or other slide programs).  

GENERAL INFORMATION FOR ORAL PRESENTERS AND MODERATORS

Presentation Development and Slide Submission 
  • Presentation Length: In general, Oral abstract presenters are asked to prepare an 8-minute presentation. An optimal 8-minute presentation has 8 content slides not including the 1 title slide provided. The session moderators will cut off presentations longer than 8 minutes. 
  • Presentation Contents: Refer to the Guidelines for Presentation Development below for slide format and details on content to be included or excluded in presentations 
  • Final Slide Submission: The final version of the presentation slides must be submitted in the Speaker Ready Room at CROI (refer to the conference program for location) 24 hours before the start of the session. 

 

Check-In on Session Day 

Presenters and moderators should check in at the front of the session room (near the podium) 10 minutes before the start of the session. The first group of presenters will then be seated on the stage. Following the first segment, the second group will be seated on the stage. 

Session Flow 

Oral sessions generally have 8 presentations, sometimes 9. Many attendees move from session to session; THEREFORE, IT IS ESSENTIAL THAT EACH PRESENTATION IS KEPT TO TIME. Before the session begins, Presenter Group 1 and the Oral Session Moderators take the stage. Regardless of the number of presentations, sessions will follow the same general flow: 

1. Oral Session Moderators: Welcome and introduce Presenter Group 1 (5 minutes). Oral moderators introduce each speaker before their presentation.  

2. Presenter Group 1 

  1. Presenter 1 (8-minute presentation, no Q&A) 
  2. Presenter 2 (8-minute presentation, no Q&A) 
  3. Presenter 3 (8-minute presentation, no Q&A) 
  4. Presenter 4 (8-minute presentation, no Q&A) 

3. Group Q&A 1: Audience Questions and Answers for Presenter Group 1. Priority will be given to questions from the microphone in the sessions, with an option to submit questions electronically. 

4. Transition: Presenter Group 1 leaves the stage, and Presenter Group 2 joins the stage 

5. Oral Session Moderators: Introduce Presenter Group 2 (5 minutes). Oral moderators introduce each speaker before their presentation. 

6. Presenter Group 2:  

  1. Presenter 5 (8-minute presentation, no Q&A) 
  2. Presenter 6 (8-minute presentation, no Q&A) 
  3. Presenter 7 (8-minute presentation, no Q&A) 
  4. Presenter 8 (8-minute presentation, no Q&A) 

7. Group Q&A 2: Audience Questions and Answers for Presenter Group 2, moderated by the Oral Session Moderators. If time remains (and at the discretion of the moderators), additional questions may be posed to Presenter Group 1 

8. Oral Session Moderators: Wrap up the session with thanks to the audience and presenters 

GUIDELINES FOR PRESENTATION DEVELOPMENT

Slide Format 
  • Slide Template: You are welcome to use the CROI Slide Template (optional) for a professional look that is consistent with the CROI branding 
  • Title Slide: A prepopulated title slide is provided for you. See above. 
  • Format: When preparing your presentation, note that high-definition (HD) projectors will be used for all CROI sessions. Please apply widescreen formatting when preparing your slides (aspect ratio 16:9; resolution 1920 x 1080) 
  • Font Size: For content slides, it is generally recommended to have a font size of 26 to 32 (based on Arial font) for text. This provides for around 7 lines of text, including a header. Details should be visible from the back of a large ballroom (avoid overly detailed figures or large blocks of text) 
  • Embedded Videos: Please test any embedded videos in the Speaker Ready room prior presentation. 
Trade Names 

Trade names for drugs should not be used in presentations. Refer to drugs and products by their nonproprietary names. 

Acknowledgments of Support and Contributors 

Acknowledgments of support may be included in the poster presentation of the abstract at CROI.  

Sex Stratification and Other Demographic Variables 

Presentations from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. For human clinical or epidemiologic studies, the presentation should provide sex-stratified results or identify who was included if it includes only a single population. Presentations of preclinical data including the use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex (as assigned at birth) or gender (where gender is relevant to the study results), this should be identified as a limitation in the study. 

See: ICMJE Preparing for Submission 

Use of People-First Language and Appropriate Terminology 

It is important to use “people first” language such as “people with HIV” rather than “HIV-infected people.” Similarly, do not characterize people by their conditions. “People with diabetes” is preferred over “diabetics”; “patients with cirrhosis” rather than “cirrhotics”; “people who inject drugs” rather than “drug abusers.” Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.” Ensure correct use of the terms sex (when reporting biologic factors) and gender (identity, psychosocial or cultural factors). Appropriate terminology such as “cisgender” (people whose gender matches the sex assigned at birth) or “transgender” (people whose gender does not match the sex assigned at birth) should be used. 

Presentations Describing New Compounds 

Please be sure to include information sufficient to allow for meaningful review of compound data; this can include isolation, activity, chemical structure, mechanism of action, toxic effects, and pharmacologic data. The chemical or molecular structure must be shown in the presentation (it need not be part of the abstract or be published in the Abstract eBook). 

PUBLICATION OR PRESENTATION PRIOR TO CROI

If study data are accepted for publication or presentation after the abstract submission to CROI, and that publication or presentation is expected to take place before CROI, the presenting author must contact CROI at CROIabstracts@iasusa.org to provide details as soon as the presentation is accepted for review, presentation, or publication in another venue or outlet. Please be aware that although publication in these circumstances will not necessarily prevent presentation of the research at CROI, our strong preference is that any additional publication or presentation happen either simultaneous to or following presentation at CROI. Requests to publish or present research accepted for presentation at CROI prior to its presentation at CROI will be evaluated on a case-by-case basis. Failure to notify the conference promptly regarding plans to publish or present a CROI-accepted abstract prior to CROI may result in the removal of the study from the conference program.